Vaxxinity (VAXX) Competitors $0.02 +0.01 (+50.00%) As of 09:46 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock VAXX vs. ADTX, SMFL, SCPS, EVLO, GNCAQ, GNCA, ARDS, STAB, AMPE, and CALAShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Aditxt (ADTX), Smart for Life (SMFL), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Aditxt Smart for Life Scopus BioPharma Evelo Biosciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals Calithera Biosciences Vaxxinity (NASDAQ:VAXX) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends. Do insiders & institutionals have more ownership in VAXX or ADTX? 82.9% of Vaxxinity shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 64.1% of Vaxxinity shares are held by company insiders. Comparatively, 0.0% of Aditxt shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher earnings and valuation, VAXX or ADTX? Aditxt has higher revenue and earnings than Vaxxinity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxxinityN/AN/A-$56.93M-$0.45-0.03Aditxt$133.99K0.77-$32.38MN/AN/A Which has more volatility & risk, VAXX or ADTX? Vaxxinity has a beta of -22.53, indicating that its share price is 2,353% less volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500. Does the MarketBeat Community prefer VAXX or ADTX? Vaxxinity received 1 more outperform votes than Aditxt when rated by MarketBeat users. However, 44.44% of users gave Aditxt an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote. CompanyUnderperformOutperformVaxxinityOutperform Votes538.46% Underperform Votes861.54% AditxtOutperform Votes444.44% Underperform Votes555.56% Is VAXX or ADTX more profitable? Vaxxinity's return on equity of 0.00% beat Aditxt's return on equity.Company Net Margins Return on Equity Return on Assets VaxxinityN/A N/A N/A Aditxt N/A -439.07%-122.96% Does the media refer more to VAXX or ADTX? In the previous week, Aditxt had 5 more articles in the media than Vaxxinity. MarketBeat recorded 5 mentions for Aditxt and 0 mentions for Vaxxinity. Aditxt's average media sentiment score of 1.52 beat Vaxxinity's score of 0.00 indicating that Aditxt is being referred to more favorably in the news media. Company Overall Sentiment Vaxxinity Neutral Aditxt Very Positive SummaryAditxt beats Vaxxinity on 6 of the 11 factors compared between the two stocks. Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.90M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-0.039.0626.7119.71Price / SalesN/A251.50386.13120.55Price / CashN/A65.8538.2534.62Price / Book0.146.456.774.50Net Income-$56.93M$143.98M$3.23B$248.22M7 Day PerformanceN/A2.41%1.80%0.56%1 Month PerformanceN/A4.56%11.10%13.17%1 Year PerformanceN/A-2.67%17.11%7.30% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.02+50.0%N/A-88.0%$1.90MN/A-0.0390Gap UpHigh Trading VolumeADTXAditxt0.8733 of 5 stars$1.63-8.9%N/A-100.0%$93,000.00$133,985.000.0060Positive NewsEarnings ReportGap UpSMFLSmart for LifeN/A$0.00-82.9%N/A-100.0%$21,000.00$11.11M0.00110Gap UpHigh Trading VolumeSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$6,000.00N/A0.00120Gap UpGNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.8%$5,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-85.7%$5,000.00N/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00+11.1%N/A-98.8%$3,000.00N/A0.0020Gap UpCALACalithera BiosciencesN/A$0.00+500.0%N/A-97.0%$3,000.00N/A0.0060Analyst Forecast Related Companies and Tools Related Companies Aditxt Competitors Smart for Life Competitors Scopus BioPharma Competitors Evelo Biosciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Ampio Pharmaceuticals Competitors Calithera Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VAXX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
